Rusalatide

Drug Profile

Rusalatide

Alternative Names: Chrysalin; Rusalatide acetate; Thrombin receptor activating peptide; TP 508; TRAP-508

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas Medical Branch
  • Developer Baylor College of Medicine; Capstone Therapeutics; Chrysalis BioTherapeutics; Quintiles; University of Texas Medical Branch
  • Class Peptides; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Apoptosis stimulants; Cytokine modulators; Intercellular signalling peptide and protein stimulants; Nitric oxide stimulants; Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Radiation injuries
  • Discontinued Chronic wounds; Diabetic foot ulcer; Fracture; Joint disorders; Myocardial infarction; Periodontal disorders; Spinal disorders; Vascular disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Radiation-injuries in USA (Parenteral)
  • 23 Sep 2013 Rusalatide licensed to Chrysalis BioTherapeutics worldwide
  • 23 Sep 2013 Chrysalis BioTherapeutics receives grant from National Cancer Institute for Rusalatide development in Radiation injuries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top